Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 4;11(6):1636.
doi: 10.3390/biomedicines11061636.

Combined Pulmonary Fibrosis and Emphysema: Comparative Evidence on a Complex Condition

Affiliations
Review

Combined Pulmonary Fibrosis and Emphysema: Comparative Evidence on a Complex Condition

Diana Calaras et al. Biomedicines. .

Abstract

Combined pulmonary fibrosis and emphysema (CPFE) is a clinical syndrome characterized by upper lobe emphysema and lower lobe fibrosis manifested by exercise hypoxemia, normal lung volumes, and severe reduction of diffusion capacity of carbon monoxide. It has varying prevalence worldwide with a male predominance, and with smoking history of more than 40 pack-years being a common risk factor. The unique imaging features of CPFE emphasize its distinct entity, aiding in the timely detection of pulmonary hypertension and lung cancer, both of which are common complications. High-resolution computed tomography (HRCT) is an important diagnostic and prognostic tool, while lung cancer is an independent factor that alters the prognosis in CPFE patients. Treatment options for CPFE are limited, but smoking cessation, usual treatments of pulmonary fibrosis and emphysema, and avoidance of environmental exposures are encouraged.

Keywords: emphysema; interstitial lung disease; lung fibrosis; lung function; pulmonary hypertension.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Factors associated with Combined Pulmonary Fibrosis and Emphysema. Abbreviations: IPF—idiopathic pulmonary fibrosis, CTD-ILD—connective tissue disease-associated interstitial lung disease, RA-ILD—rheumatoid arthritis-associated interstitial lung disease, SS-ILD—systemic sclerosis-associated interstitial lung disease, c-ANCA—antineutrophil cytoplasmic autoantibody, fHP—fibrotic hypersensitivity pneumonitis.
Figure 2
Figure 2
HRCT patterns in CPFE. A predominant pattern of centrilobular emphysema in the upper lobes and a thick-walled cyst in the lower left lung zone in a field of fibrotic lesions in a 60-year-old patient diagnosed with idiopathic pulmonary fibrosis.
Figure 3
Figure 3
Progressive transition HRCT pattern of CPFE. The typical distribution: predominant pattern of centrilobular emphysema in the upper lobes, extending to a panlobular emphysema in the midzones, and an isolated area of centrilobular emphysema in the left lower lobe in the field of subpleural reticular opacities, traction bronchiectasis, and bronchioloectasis in a 59-year-old patient with fibrotic hypersensitivity pneumonitis with a history of 30 pack-years of smoking.
Figure 4
Figure 4
HRCT pattern of emphysema admixed with DIP. Areas of low attenuation (emphysema) are mixed with ground-glass opacities (areas of high attenuation) and periemphysematous thickening.

References

    1. Auerbach O., Garfinkel L., Hammond E.C. Relation of Smoking and Age to Findings in Lung Parenchyma: A Microscopic Study. Chest. 1974;65:29–35. doi: 10.1378/chest.65.1.29. - DOI - PubMed
    1. Cottin V., Nunes H., Brillet P.-Y., Delaval P., Devouassaoux G., Tillie-Leblond I., Israel-Biet D., Court-Fortune I., Valeyre D., Cordier J.-F. Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity. Eur. Respir. J. 2005;26:586–593. doi: 10.1183/09031936.05.00021005. - DOI - PubMed
    1. Safiri S., Carson-Chahhoud K., Noori M., Nejadghaderi S.A., Sullman M.J.M., Heris J.A., Ansarin K., Mansournia M.A., Collins G.S., Kolahi A.-A., et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: Results from the Global Burden of Disease Study 2019. BMJ. 2022;378:e069679. doi: 10.1136/bmj-2021-069679. - DOI - PMC - PubMed
    1. Maher T.M., Bendstrup E., Dron L., Langley J., Smith G., Khalid J.M., Patel H., Kreuter M. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir. Res. 2021;22:197. doi: 10.1186/s12931-021-01791-z. - DOI - PMC - PubMed
    1. Cottin V., Hansell D.M., Sverzellati N., Weycker D., Antoniou K.M., Atwood M., Oster G., Kirchgaessler K.-U., Collard H.R., Wells A.U. Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2017;196:1162–1171. doi: 10.1164/rccm.201612-2492OC. - DOI - PubMed

LinkOut - more resources